Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.

Abstract

BACKGROUND:

Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux. Response of laryngitis to treatment with acid-suppressive therapy supports this causal link.

AIM:

To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and response to proton-pump inhibitor therapy.

METHODS:

Patients with chronic laryngitis were recruited. The frequency and severity of reflux and laryngeal symptoms were scored and laryngitis graded by laryngoscopy. All patients underwent esophagogastroduodenoscopy and 24-h ambulatory pH monitoring before receiving lansoprazole 30 mg b.d. for 8 weeks.

RESULTS:

The prevalence of gastro-oesophageal reflux disease was 65.6% (21 of 32). Based on positive pH test, the prevalence was 25% (eight of 32). The change in laryngeal symptom score and laryngitis grade was significantly higher in GERD compared with non-GERD patients (P = 0.010 for both). The proportion of patients with marked/moderate improvement in laryngeal symptoms were significantly higher in patients with reflux (14 of 21, 67%) compared to those without reflux (two of 11, 18%; P = 0.026).

CONCLUSIONS:

The prevalence of gastro-oesophageal reflux disease amongst our patients with chronic laryngitis was high. The response to treatment with proton-pump inhibitors in patients with reflux disease compared to those without underlined the critical role of acid reflux in a subset of patients with chronic laryngitis.

• Authors: C S Qua, C H Wong, K Gopala, K L Goh
• Journal: Alimentary pharmacology & therapeutics (Aliment Pharmacol Ther) Vol. 25 Issue 3 Pg. 287-95 (Feb 01 2007) ISSN: 0269-2813 [Print] England
• PMID: 17269990 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Proton Pump Inhibitors
• Proton Pumps
• Lansoprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (therapeutic use)
• Adult
• Anti-Ulcer Agents (therapeutic use)
• Cohort Studies
• Female
• Gastroesophageal Reflux (complications)
• Humans
• Lansoprazole
• Laryngitis (etiology)
• Male
• Middle Aged
• Prospective Studies
• Proton Pump Inhibitors
• Proton Pumps (therapeutic use)